Active	Status	Sponsor type	Region	Phase	Filter
4 Active 5 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chang, Chi-Yang
NCT06156085: Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy	Recruiting	4	318	RoW	Vonoprazan and Amoxicillin, Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole	Fu Jen Catholic University Hospital	Helicobacter Pylori Infection	06/25	12/25
NCT05842512: Study of ADI-PEG 20 Versus Placebo in Subjects With NASH	Recruiting	2	40	RoW	ADI-PEG20, Pegargiminase, Placebo	Polaris Group	Nonalcoholic Steatohepatitis (NASH)	12/27	01/28
NCT05092074: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection	Recruiting	N/A	100	RoW	Vosevi 400/100/100 Oral Tablet	National Taiwan University Hospital	Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment, Effect of Drug	12/22	02/23
NCT05402449: To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation	Completed	N/A	70	RoW	Placebo, Control group, Probiotics, Test group	GenMont Biotech Incorporation, Fu Jen Catholic University Hospital	Non-Alcoholic Fatty Liver Disease	05/24	05/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chang, Chi-Yang
NCT06156085: Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy	Recruiting	4	318	RoW	Vonoprazan and Amoxicillin, Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole	Fu Jen Catholic University Hospital	Helicobacter Pylori Infection	06/25	12/25
NCT05842512: Study of ADI-PEG 20 Versus Placebo in Subjects With NASH	Recruiting	2	40	RoW	ADI-PEG20, Pegargiminase, Placebo	Polaris Group	Nonalcoholic Steatohepatitis (NASH)	12/27	01/28
NCT05092074: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection	Recruiting	N/A	100	RoW	Vosevi 400/100/100 Oral Tablet	National Taiwan University Hospital	Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment, Effect of Drug	12/22	02/23
NCT05402449: To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation	Completed	N/A	70	RoW	Placebo, Control group, Probiotics, Test group	GenMont Biotech Incorporation, Fu Jen Catholic University Hospital	Non-Alcoholic Fatty Liver Disease	05/24	05/24